Neutrophils are the body's main defence against invasion by bacteria and fungi and, below a level of 1 × 10 9 /l, there is a direct relationship between their circulating number and the risk of systemic infection. Despite advances in supportive care, such as improved broad-spectrum antibiotics and the haemopoietic growth factors, neutropenia following myelosuppressive chemotherapy for malignant disease remains the most important cause of treatment-related morbidity and mortality and its most important dose-limiting toxicity. Although there is clear theoretical, experimental and anecdotal clinical evidence supporting the use of transfused granulocytes to prevent and treat infection in neutropenia, early attempts at exploiting this clinically were unsuccessful, mainly because of difficulties in collecting a sufficient number of cells. Improvements in the technology of collection, including the use of red cell sedimenting agents, glucocorticoids and, more recently, granulocyte-colony-stimulating factor, now allow granulocyte doses within the therapeutic range to be routinely collected. Preliminary evidence suggests clinical efficacy. However, well-designed trials with clinically relevant end-points will be required before granulocyte transfusion can become part of routine clinical practice.
Introduction
Improvements in the transfusion support of patients with bone marrow failure have been a major factor in the development of modern haemato-oncology. Despite considerable effort, the main area in which transfusion medicine has failed to make an impact has been in the support of neutropenia, which remains an important clinical problem. This review will summarize the biological and theoretical aspects of granulocyte transfusion and discuss previous clinical studies, as well as the more recent developments, particularly the use of granulocyte-colony-stimulating factor (G-CSF) as an adjunct to the collection of granulocytes from normal donors. (The term granulocyte includes neutrophils, eosinophils and basophils. Granulocyte concentrates contain all of these cell types, although neutrophils predominate and are the cell type required for therapeutic effect. The terms neutrophil and granulocyte will be used interchangeably in this review.)
Neutrophil kinetics and function
The kinetics of granulocyte production were elucidated in the 1960s in a series of seminal experiments performed by Wintrobe, Athens, Cartwright and others [1, 2] . Radiolabelled granulocytes were administered to normal individuals to establish the size of the functional pools and the rate of cell production and cell loss. Granulocytes derive from an undifferentiated stem cell pool from which committed proliferating progenitors develop under the influence of haematopoietic growth factors (HGFs). Transit through the proliferating pool is associated with progressive lineage restriction and the development of functional and phenotypic characteristics of mature cells. After a variable time-period of storage in the bone marrow, neutrophils are released into the peripheral blood where they circulate for ≈ 6 h in dynamic equilibrium with a marginated pool of cells that are loosely adherent to the vascular endothelium. In response to cytokines and chemoattractants, neutrophils migrate through vascular endothelium into the tissues where they phagocytose and kill micro-organisms by a variety of mechanisms, including oxygen radicals generated by the respiratory burst, nitric oxide and specific antimicrobial proteins. Although neutrophils can recognize protein and lipid components of the bacterial cell wall, phagocytosis is greatly enhanced by opsonization with antibody or complement. The size and transit times through the various granulocyte pools are shown in Fig. 1 .
Theoretical basis of granulocyte transfusion
The key role of neutrophils in defence against bacterial and fungal infection is underlined by the clinical consequences of abnormalities in their number or function. Below a level of 1 × 10 9 /l there is a significant risk of infection, which is proportional to the severity and duration of the neutropenia [3] . Chemotherapy of malignant disease is currently the commonest cause of neutropenia, however, primary bone marrow abnormalities and neutrophil function defects result in a similar pattern of infection. Experimental studies in neutropenic dogs, to which donor granulocytes were administered as protection against Pseudomonas septicaemia , revealed that a threshold dose of 2 × 10 8 /kg ensured protection from an otherwise lethal infection [4] . The cell dose vs. survival curve was steep, with uniform mortality in animals receiving a neutrophil dose of < 1·5 × 10 8 /kg.
Granulocyte collection
Collection of the large cell doses predicted from the above studies is extremely challenging as the normal human circulating neutrophil pool is 30 × 10 7 /kg and the daily therapeutic dose suggested by the canine experiments is > 15 × 10 7 /kg. In practice this has meant the pooling of multiple donations, the use of donors with an expanded neutrophil pool, for example patients with chronic myeloid leukaemia (CML), or the administration of agents such as glucocorticoids or G-CSF to normal individuals. Significant and sustained neutrophil increments in the recipient of CML products have been observed and there are anecdotal reports of clinical efficacy [5] . Owing to the rarity of CML, normal volunteer donors pretreated with G-CSF and/or glucocorticoids are the only realistic source of granulocytes in most situations.
Collection techniques
Granulocyte concentrates may be obtained by pooling buffy coats from normal blood donations. Although these products are sometimes used, at least 12 donor units are required for an adult dose of granulocytes. A randomized trial in paediatric patients showed no beneficial effect [6] and, given the large donor exposure and logistical problems, it is difficult to recommend their continued use. Previously, granulocytes were harvested by adherence to nylon fibres [7] but because of toxicity to donor and recipient and lack of efficacy, this technique is no longer used. Most recent studies have used granulocytes harvested from normal donors by apheresis techniques.
Adjuncts to collection

Sedimenting agents
The use of a red cell sedimenting agent results in greater separation of the granulocyte component and better yield [8] . Several such agents have been evaluated, including dextran [8, 9] , hydoxyethyl starch (HES), a lower molecular-weight preparation of HES called pentastarch [10, 11] and modified gelatin derivatives such as plasmagel [12, 13] . Because of the incidence of allergic reactions, dextran has been superseded by HES and pentastarch. A study aimed at optimizing the dose of pentastarch showed no advantage above 500 ml of a 10% solution and this has been widely adopted [10] .
Glucocorticoids
Corticosteroids increase marrow release of granulocytes, decrease efflux from the blood [14] and reduce the circulating Fig. 1 The kinetics of neutrophil production showing the approximate size, transit times and output of the various functional pools [50] . lymphocyte count, all of which benefit granulocyte collection. A single dose of dexamethasone, 8 mg p.o., 12-24 h before apheresis, works well with few side-effects [15, 16] .
G-CSF
G-CSF is a protein secreted by a variety of cell types, including bone marrow stromal cells, macrophages, fibroblasts and endothelial cells [17] . It functions as an important regulator of both steady-state and 'emergency' granulopoiesis and enhances the function of mature granulocytes.
G-CSF has been in routine clinical use for more than a decade with remarkably few reports of adverse events. Side-effects include bone pains, fatigue, headache, nausea and occasional fever. Although initially restricted to use in patients, the excellent safety profile of G-CSF has encouraged its use in normal donors. Some safety concerns remain, predominantly relating to leucostasis, possible thromboembolic complications and the prospect of leukaemogenic effects. A single dose of G-CSF should not result in a neutrophilia sufficient to cause leukostasis or thrombosis, and if G-CSF can induce leukaemia it probably requires long-term exposure. Nonetheless, it is probably wise to limit the age of donors and exclude those with known vascular, inflammatory or autoimmune disease [18] . A final concern relates to the induction of splenomegaly and occasional reports of splenic rupture in individuals receiving G-CSF [19] , although again this has occurred after repeated dosage. Data on the long-term follow-up of normal subjects treated with G-CSF is extremely sparse with no abnormality noted in those few subjects reported to date [20, 21] .
Current protocols
Comparison of different mobilizing regimes
Prior to the introduction of G-CSF, the usual yield of granulocytes from a 10 l apheresis was ≈ 3·3 × 10 9 with corticosteroids and 2·0 × 10 9 without [22] . As discussed above, this is at least an order of magnitude below what is required for biological activity. There have been two major strategies for the use of G-CSF as an adjunct to granulocyte collection. Both entail the concurrent use of G-CSF and corticosteroids, which appears to be superior to the use of G-CSF alone [23] . The most common protocol involves a single administration of corticosteroid (usually 8 mg of dexamethasone) and a single dose of 5-10 µ g/kg of G-CSF, followed by apheresis using citrate anticoagulant and 500 ml of 10% pentastarch as a sedimenting agent 12-24 h later. Reported yields using this protocol are remarkably consistent at 7·74 ± 6·4 × 10 10 [16] , 8·3 ± 2·4 × 10
10
[24] and 10·5 × 10 8 /kg [25] . An alternative approach has been repeated administration of G-CSF and daily or alternate-day aphereses [26, 27] . This has the advantage of reducing the number of donors required but the disadvantage of increased risk to the donor. Of particular concern is the donor platelet count, which may decrease by as much as 30 -50% after each procedure [18] . For this reason alone, a single procedure would seem preferable.
Donor selection
Given the similarity of the procedures, the same donor selection criteria apply as for platelet apheresis donors. Granulocyte concentrates contain significant numbers of red blood cells and should therefore be an ABO RhD match with the recipient. In view of the potential risk of thrombotic complications, particularly in those with occult cardiovascular disease, it has been our practice not to use donors who are older than 45 years of age, and to screen by performing a full physical examination, chest radiograph and electrocardiogram. In addition, in cases where allogeneic transplantation is contemplated, use of family members is best avoided because of the risk of immunization against minor histocompatibility antigens.
Properties of harvested granulocytes
A study of neutrophils mobilized from healthy donors using G-CSF and dexamethasone, then harvested using HES [16] , revealed an increase in the surface expression of CD11b, CD18, CD14, CD32 and CD34, together with shedding of L -selectin. The cells had normal bactericidal activity against Staphylococcus aureus , but a somewhat reduced respiratory burst to some, but not all, agonists. Following transfusion, the blood half-life of the remaining cells was increased compared to non-G-CSF-mobilized cells, possibly because of the antiapoptotic effects of G-CSF and glucocorticoids [28, 29] . Migration of the mobilized neutrophils into skin chambers was comparable to the subjects' own neutrophils, premobilization, and the authors concluded that the functional properties of the collected neutrophils were near normal.
Storage
Granulocytes can be stored at room temperature for up to 8 h without reduction of their ability to circulate or migrate to a site of inflammation [30] . More recently, killing of Candida albicans was shown to be preserved in 20-h-old granulocytes treated with G-CSF and interferon-γ [31] . A study of normal donor G-CSF/dexamethasone-mobilized granulocytes stored at various temperatures in the presence or absence of supplemental G-CSF, showed a decrease with time of L -selectin but maintenance of CD11b, CD18, CD14, CD16, CD32 and CD64 levels [32] . Respiratory burst activity was retained best at 10 ° C and there was no impact of additional G-CSF. Cells stored for up to 24 h at 10 ° C retained their capacity to circulate in normal subjects (normal t 1/2 ) and to migrate into a skin window. Therefore, although it is usually recommended that granulocytes are best given with minimal delay, storage at 10 ° C for up to 24 h may be possible.
Clinical studies of granulocyte transfusion
There have as yet been no controlled trials of G-CSF-mobilized granulocyte transfusion, and evidence of efficacy therefore rests on uncontrolled series, anecdotal reports and extrapolation from previous studies of non-mobilized cells. These studies fall into two major categories: prophylactic trials in which granulocytes are given to neutropenic patients to prevent infection; and therapeutic studies in which granulocyte transfusions are used as an adjunct to antibiotics in neutropenic patients with established infection.
Prophylactic use
A recent meta-analysis of the eight randomized, controlled trials of prophylactic granulocyte transfusion published from 1970 to 1995 showed that outcomes varied according to assessment of leucocyte compatibility prior to transfusion, dose of granulocytes infused and duration of neutropenia [33] . It also demonstrated that transfusion of adequate doses of compatible leucocytes significantly reduced the relative risk of infection, death and death from infection in transfused patients. As alloimmunization after granulocyte transfusion is relatively common, regular screening for alloantibodies or granulocyte crossmatching would seem advisable.
Therapeutic use
A number of controlled trials of therapeutic granulocyte transfusion have been reported [34] [35] [36] [37] [38] [39] [40] . The three studies reporting positive results [35, 37, 38] gave granulocyte doses of 1·7-2·7 × 10 10 , whilst the negative studies gave doses of 0·4-0·5 × 10
10
. A meta-analysis of these seven studies [41] concluded that the significant variables responsible for differing success rates were the dose of granulocytes infused and the survival rate of the non-transfused control group. In addition, a number of uncontrolled studies and reports are strongly suggestive of the fact that the judicious use of granulocyte therapy can be life saving in infected neutropenic patients. Amongst the most impressive are favourable responses in 11 of 15 patients with neutropenia and amphotericin B-resistant invasive fungal infection [42] , resolution of infection in eight of 11 patients with bacterial infection or candidaemia [24] and survival to day 100 of 14/23 patients with severe bacterial or fungal infection [43] .
Adverse events
Any of the complications of other blood components can occur following granulocyte transfusion. It is particularly important for recipients who are potential recipients of bone marrow transplantation to receive granulocytes from donors of appropriate cytomegalovirus (CMV ) status. Granulocyte concentrates are inevitably heavily contaminated with lymphocytes and therefore routine irradiation of all granulocyte donations (2·5 Gy) is obligatory to avoid transfusionassociated graft-vs.-host disease.
Alloimmunization against human leucocyte antigen (HLA) and granulocyte antigens
Alloimmunization of the recipients of combined platelet and granulocyte transfusion has long been recognized [44] and has been associated with severe transfusion reactions. A recent report [45] of alloimmunization following granulocyte transfusions revealed the presence of white cell antibodies in 14/18 recipients, of which eight were against antigens other than HLA. Of the 14 alloimmunized patients, 11 experienced transfusion reactions whilst none were observed in the nonimmunized recipients.
Pulmonary infiltrates
Pulmonary infiltrates have been an important adverse event in a number of the clinical trials of granulocyte transfusion. Although the precise mechanism of infiltrate formation is unclear, it is known that infused granulocytes initially home to the pulmonary circulation and this effect can be enhanced in the presence of cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) [46] . It is possible therefore that initial homing of transfused granulocytes to the lung, combined with the local release of cytokines during pulmonary infection, could lead to inappropriate accumulation of neutrophils in the lung and consequent tissue damage. Pulmonary infiltrates are also more common in alloimmunized patients, presumably because of antibody-mediated neutrophil activation or aggregation. Granulocyte transfusion is therefore contraindicated in the presence of alloimmunization or severe respiratory abnormalities.
An early report [47] implicated the combination of amphotericin B and granulocyte transfusion in lethal pulmonary reactions. Although subsequent reports have disputed this [48, 49] , most groups still recommend the precaution of separating the administration of granulocytes and amphotericin B by several hours.
Conclusion
Stimulation of normal donors with G-CSF will routinely yield apheresis granulocyte doses within the predicted therapeutic range. Well-designed randomized, controlled trials of both prophylactic and therapeutic granulocyte support are, however, required before the modality is more widely adopted. In order to minimize adverse reactions, the identification of alloimmunized recipients, either by repeated antibody screening or by granulocyte crossmatching, will be necessary. The logistical difficulty of performing these studies will be considerable and will require close multicentre collaboration between transfusion specialists and clinicians.
